期刊文献+

实时荧光RT-PCR定量检测前列腺癌组织中AMACR基因表达 被引量:2

Quantitative detection of AMACR mRNA in prostate cancer tissues by real-time fluorescent quantitative reverse transcription polymerase chain reaction (FQ-RT-PCR) and the clinical significance
原文传递
导出
摘要 目的建立实时荧光定量逆转录聚合酶链反应(FQ-RT-PCR)检测AMACR mRNA的方法学并检测其在前列腺癌(PCa)组织中的表达。方法在AMACR基因的2、3外显子之间设计一对引物及MGB探针,将PCR扩增产物与pMD18-T载体连接,构建重组质粒作为定量检测的标准品,建立实时荧光定量RT-PCR方法,然后对32例PCa、60例良性前列腺增生(BPH)及34例其它肿瘤组织进行AMACR mRNA的定量检测。结果重组质粒经PCR扩增及序列测定,表明克隆成功,该方法灵敏度高,线性范围为5~5×108copies/reaction。AMACR mRNA在PCa组织中表达量显著高于BPH组织(P<0.01)及其他类型肿瘤组(P<0.01)。ROC曲线分析结果显示,曲线下面积(AUC-ROC)为0.890,AMACR mRNA诊断前列腺癌的敏感度和特异度分别为81.3%和86.7%。PCa组织中AMACR mRNA表达量及检测阳性率与不同临床分期和病理分级之间的差异尚不具有统计学意义(P值均>0.05)。结论实时荧光定量RT-PCR检测AMACR mRNA的方法具有敏感、特异、准确、重复性好等特点。AMACR mRNA在前列腺组织中的表达对PCa的诊断具有一定的临床应用价值。 Objectives To establish the real-time fluorescent quantitative reverse transcription polymerase chain reaction(FQ-RT- PCR) for the expression of AMACR mRNA in the prostate tissues. Methods A Taqman-MGB probe and a pair of primers were designed between exon 2 and 3. The PCR products were inserted into the pMD18-T vector and transfected into DH5 α as the standard substance for the standard curve. AMACR mRNAin the tissues of 32 prostate cancer (Pca), 60 benign prostate hypertrophy (BPH) and 34other tumor tissues was detected by real-time FQ-RT-PCR. Results FQ-RT-PCR for AMACR mRNA was successfully established. The sensitivity was 5 copies/reaction, the linear range was from 5~5× 10^8copies/reaction. The expression of AMACR mRNA in PCa tissues was notably higher in PCa tissues than that in BPH tissues(P〈0.0l) and in other tumor tissues (P〈0.01). The ROC-AUC was 0.890. The sensitivity and specificity were 81.3% and 86.7% respectively. The difference of the expression of AMACR mRNA among different clinic~ stages and different extents of differentiation was not significant statistically (P〉0.05). Conclusion Real-time FQ-RT-PCR for AMACR mRNA was sensitive, specific, rapid and efficient method. The detection of the expression of AMACR mRNA by real-time FQ- RT-PCR in prostate tissues may be of great value in the diagnosis of prostate cancer.
出处 《中国男科学杂志》 CAS CSCD 2008年第4期14-19,共6页 Chinese Journal of Andrology
关键词 基因 前列腺肿瘤/诊断 逆转录聚合酶链反应 genes prostatic neoplasms/diagnosis reverse transcriptase polymerase chain raction
  • 相关文献

参考文献13

  • 1Xu J, Stolk JA, Zhang X, et al. Identification of differentially expressed genes in human prostate cancer using subtractionand microarray. Cancer Res 2000; 60(6): 1677-1682
  • 2Jiang Z, Woda BA, Rock KL, et al. P504S: a new moleculer marker for the detection of f prostatic cancer. Am J Surg Pathol 2001; 25(11): 1397-1404
  • 3Rubin MA, Zhou M, Dhanasekaran SM, et al. Alpha- Methylacyl-CoA Racemase as a tissue biomarker for prostate cancer. JAMA 2002; 287(13): 1662-1670
  • 4Lczkowski KA, Jiang Z, Tretiakova M, et al. Prostate needle biopsies with suspicious (ASAP) diagnosis:80% resolved using P504S/AMACR and keration34E12 immunostaining. Mod Pathol 2003; 16: 154A
  • 5Beach R, Gown AM, Peralta-Venturina MN, et al. P504S cal detection in 405 prostatic specimens including 376 18-gauge needle biopsies, Am J Surg Pathol 2002; 26(12): 1588-1596
  • 6Kunju LP, Rubin MA, Shen R, et al. Comparison of monoclonal antibody (P504S) and polyclonal antibody to Alpha-met hylacyl CoA racemase in benign atypical and malignant prostate tissue. Mod Pathol 2003; 16: 158A
  • 7Arum St reekumar, Bharat hi Laxman, Daniel R Rhodes, et al. Humoral immune response to Alpha-met hylacyl-CoA racemase and prostate cancer. JNCI 2004; 96 (11): 834-843
  • 8Carter HB, Isaacs WB. Improved biomarker for prostate cancer: A definite need. JNCI 2004; 96(11): 813-815
  • 9Jiang Z, Wu CL, Woda BA, et al. Alpha-methylacyl-CoA racemase: a multil- institutional study of a new prostate cancer marker. Histopathology 2004; 45(3): 218:225
  • 10Zhou M, Aydin H, Kanane H, et al. How often does Alphamet hylacyl-CoA racemase contribute to resolving an atypical diagnoss on prostate needle biopsy beyond that provided by basal cell markers? Am Surg Pathol 2004; 28(2): 239-243

同被引文献40

  • 1孙月庭,刘斌剑,何善述.前列腺特异性抗原在诊断前列腺疾病中的研究进展[J].国际检验医学杂志,2006,27(6):548-550. 被引量:14
  • 2毛晓露,陶志华,徐伟,陈晓东,陈占国,翁志梁,胡元平,吴秀玲,张筱骅,谢辉,王瓯晨,宋其同,李澄棣,余凯远.DD3和PSA基因在前列腺癌组织中的定量表达分析[J].中华泌尿外科杂志,2006,27(9):624-627. 被引量:6
  • 3毛晓露,陶志华,陈晓东,陈占国,林晓梅,王瑜敏,朱燕英,温秀姝,余凯远.荧光实时定量RT-PCR检测DD3mRNA方法的建立[J].临床检验杂志,2006,24(5):335-337. 被引量:3
  • 4Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer, Cancer Res, 1999, 59(23): 5975-5979.
  • 5Marks LS, Bostwick DG. Prostate cancer specificity of PCA3 gene testing: examples from clinical practice, Rev Urol, 2008, 10(3): 175-181.
  • 6Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer, Nat Rev Urol, 2009, 6(5): 255-261.
  • 7Culig Z, Steiner H, Barstsch G, et al. Mechanisms of endocrine therapy-responsive and unresponsive prostate tumours, Endocr Relat Cancer, 2005, 12(2): 229-244.
  • 8Steiner MS, Gingrich JR. Gene therapy for prostate cancer:where are we now, J Urol, 2000, 164(4): 1121-1136.
  • 9Koeneman KS, Kao C, Ko SC, et al. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis, World J Urol, 2000, 18(2): 102-110.
  • 10Xu J, Stolk JA, Zhang X, et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray, Cancer Res, 2000, 60(6): 1677-1682.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部